SCHEMBL321003

SCHEMBL321003

CCc1cccc(N)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.45
GABRB2 P47870 2/20 0.45
BID P55957 3/20 0.44
MCL1 Q07820 3/20 0.44
PPARA Q07869 3/20 0.44
BCL2L1 Q07817 2/20 0.44
BAK1 Q16611 2/20 0.44
KAT8 Q9H7Z6 2/20 0.44
PPARG P37231 2/20 0.44
EP300 Q09472 1/20 0.44
KAT2A Q92830 1/20 0.44
KAT2B Q92831 1/20 0.44
KAT5 Q92993 1/20 0.44
SAE1 Q9UBE0 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10489825 0.87 BID (0.51) BIDMCL1PPARABCL2L1BAK1
SCHEMBL20503737 0.86 MMP2 (0.44) BIDMCL1PPARABCL2L1BAK1
SCHEMBL423306 0.85 GABRA1 (0.54) GABRA1GABRB2BIDMCL1PPARA
SCHEMBL8477665 0.84 MMP2 (0.42) BIDMCL1PPARABCL2L1BAK1
SCHEMBL8477659 0.84 MMP2 (0.42) BIDMCL1PPARABCL2L1BAK1
SCHEMBL10489741 0.84 BID (0.60) GABRA1GABRB2BIDMCL1PPARA
SCHEMBL10489945 0.83 GABRA1 (0.50) GABRA1GABRB2ALDH1A1MAPTSMN1; SMN2
SCHEMBL3260662 0.83 BID (0.68) BIDMCL1PPARABCL2L1BAK1
SCHEMBL19628955 0.82 FOLH1 (0.44) BIDMCL1BCL2L1BAK1MMP2
SCHEMBL28874207 0.82 MMP2 (0.41) BIDMCL1PPARABCL2L1BAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108976140-B Preparation method and intermediate of 2-amino-6-ethylbenzoic acid 上海医药工业研究院 2021-07-09 CN claimed
CN-108976140-A A kind of Preparation Method And Their Intermediate of 2- amino -6- ethyl benzoate 上海医药工业研究院 2018-12-11 CN claimed
WO-2011054874-A1 METHOD FOR THE PREPARATION OF 2-AMINO-6-ETHYLBENZOIC ACID ACTIVE BIOTECH AB (SE) 2011-05-12 WO claimed
EP-2316818-A1 Method for the preparation of 2-amino-6-ethylbenzoic acid Active Biotech AB (SE) 2011-05-04 EP claimed
CN-115613352-A Breathable down-proof fabric and preparation method thereof 余翔 2023-01-17 CN disclosed
CN-108976140-B Preparation method and intermediate of 2-amino-6-ethylbenzoic acid 上海医药工业研究院 2021-07-09 CN disclosed
CN-108976140-B Preparation method and intermediate of 2-amino-6-ethylbenzoic acid 上海医药工业研究院 2021-07-09 CN disclosed
CN-108976140-B Preparation method and intermediate of 2-amino-6-ethylbenzoic acid 上海医药工业研究院 2021-07-09 CN disclosed
US-10350315-B2 Quinoline-3-carboxamide compounds and their use in diagnosis Westfaelische Wihelms-Universitaet Muenster (DE) 2019-07-16 US disclosed
US-10350315-B2 Quinoline-3-carboxamide compounds and their use in diagnosis Westfaelische Wihelms-Universitaet Muenster (DE) 2019-07-16 US disclosed
CN-108976140-A A kind of Preparation Method And Their Intermediate of 2- amino -6- ethyl benzoate 上海医药工业研究院 2018-12-11 CN disclosed
CN-108976140-A A kind of Preparation Method And Their Intermediate of 2- amino -6- ethyl benzoate 上海医药工业研究院 2018-12-11 CN disclosed
EP-0322133-A1 Quinazoline derivatives SmithKline Beecham Intercredit B.V. (NL) 1989-06-28 EP disclosed
WO-1989005297-A1 COMPOUNDS SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) 1989-06-15 WO disclosed
CN-1033380-A Compound SMITHKLINE BECKMAN INTERCREDIT (NL) 1989-06-14 CN disclosed
US-4745116-A INHIBITORS OF SERINE PROTEASE SYNTEX (U.S.A.) INC. (US) 1988-05-17 US disclosed
US-4665070-A SERINE PROTEINASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1987-05-12 US disclosed
US-4657893-A ANTIINFLAMMATORY AGENTS SYNTEX (U.S.A.) INC. (US) 1987-04-14 US disclosed
EP-0206323-A1 2-Oxy-4H-3,1-benzoxazin-4-one derivatives and related compounds SYNTEX (U.S.A.) INC. (US) 1986-12-30 EP disclosed
EP-0147211-A2 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation SYNTEX (U.S.A.) INC. (US) 1985-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10350315-B2 Quinoline-3-carboxamide compounds and their use in diagnosis S100A9, S100A4, S100A10 GABRA1 3049/4885GABRB2 2569/4885BID 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.